Roivant's Priovant Announces First Patients Enrolled In Global Phase 3 BEACON+ Study Of Brepocitinib In Cutaneous Sarcoidosis; Topline Data Expected In 2028

Benzinga Newsdesk www.benzinga.com Positive 68.9%

Neg 0% Neu 0% Pos 68.9%

Comments

No comments yet. Be the first!